- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02791269
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
13. desember 2016 oppdatert av: Hoffmann-La Roche
Expanded Access Program of PEGASYS® (Peg Interferon Alpha-2a 40 KD) in Patients With HBeAg-Positive And HBeAg-Negative Chronic Hepatitis B
This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV infection.
All participants will receive 48 weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free follow-up period.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
24
Fase
- Fase 4
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Auckland, New Zealand
-
Hamilton, New Zealand
-
New Plymouth, New Zealand
-
Riccarton, Christchurch, New Zealand, 8011
-
Rotorua, New Zealand
-
Whangarei, New Zealand
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 70 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Non-cirrhotic participants
- Hepatitis B surface antigen (HBsAg) positive for at least 6 months
- Hepatitis B surface antibody (anti-HBs) negative
- Elevated serum alanine aminotransferase (ALT) greater than (>) upper limit of normal (ULN) but less than or equal to (</=) 10 times of ULN
- HBeAg positive participants: HBV DNA > 500,000 copies/mL, HBeAg negative participants: HBV DNA >100,000 copies/mL by polymerase chain reaction (PCR)
- Participants with chronic hepatitis B (CHB) who are treatment-naive
- No previous antiviral treatment with interferon (IFN: standard or pegylated) or with a nucleoside analogue
- For women of childbearing potential: negative urine or serum pregnancy test documented within the 24-hour period prior to the first dose of test drug. Willingness to use reliable contraception during the study and for 3 months after treatment completion
Exclusion Criteria:
- Previous antiviral or IFN-based therapy for CHB before enrolment
- Pregnant or breast feeding women participants
- Evidence of decompensated liver disease
- Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human immunodeficiency virus (HIV)
- History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis
- Previous or current hepatocellular carcinoma
- History of or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- Alpha-fetoprotein levels of >100 nanograms (ng)/mL
- Severe psychiatric disease
- History of a severe seizure disorder or current anticonvulsant use
- History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the participant, in the opinion of the investigator, unsuitable for the study
- Thyroid disease uncontrolled by prescribed medications
- Evidence of severe retinopathy
- Alcohol intake more than 3 standard drinks per day for men and 2 standard drinks per day for women
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HBeAg Negative Participants
HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
|
180 mcg SC injection QW for 48 weeks.
Andre navn:
|
|
Eksperimentell: HBeAg Positive Participants
HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
|
180 mcg SC injection QW for 48 weeks.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)
Tidsramme: End of 24-weeks follow-up (Week 72)
|
HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.
|
End of 24-weeks follow-up (Week 72)
|
|
Number of Participants With HBV-DNA <20,000 Copies/mL
Tidsramme: End of 24-weeks follow-up (Week 72)
|
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
|
End of 24-weeks follow-up (Week 72)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With HBV-DNA <400 Copies/mL
Tidsramme: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
|
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion
Tidsramme: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs).
Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
|
Number of Participants With Normalization of Alanine Aminotransferase (ALT) Level
Tidsramme: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased.
In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases.
Normal ALT level = less than upper limit of normal (40 units per liter).
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
|
Number of Participants With HBeAg Seroconversion
Tidsramme: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2006
Primær fullføring (Faktiske)
1. juli 2008
Studiet fullført (Faktiske)
1. juli 2008
Datoer for studieregistrering
Først innsendt
31. mai 2016
Først innsendt som oppfylte QC-kriteriene
1. juni 2016
Først lagt ut (Anslag)
6. juni 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
6. februar 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. desember 2016
Sist bekreftet
1. desember 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Leversykdommer
- Hepatitt, viral, menneskelig
- Hepadnaviridae-infeksjoner
- DNA-virusinfeksjoner
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Hepatitt, kronisk
- Hepatitt B
- Hepatitt
- Hepatitt A-virus
- Hepatitt B, kronisk
- Anti-infeksjonsmidler
- Antivirale midler
- Peginterferon alfa-2a
Andre studie-ID-numre
- ML19295
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .